Notes in Kidney cancer

To Subscribe, use this Key


Status Last Update Fields
Published 02/18/2024 GU | Kidney | 1.2.1 | RCC | Epidemiology
Published 02/18/2024 GU | Kidney | 1.2.2 | RCC | Risk factors
Published 02/18/2024 GU | Kidney | 1.3 | RCC | Biologic behaviour
Published 02/18/2024 GU | Kidney | 1.4.1 | RCC | Subtypes
Published 02/18/2024 GU | Kidney | 1.4.2. | RCC | Clear cell
Published 02/18/2024 GU | Kidney | 1.4.3 | RCC | Papillary
Published 02/18/2024 GU | Kidney | 1.4.4 | RCC | Chromophobe
Published 02/18/2024 GU | Kidney | 1.4.5 | RCC | Collecting duct
Published 02/18/2024 GU | Kidney | 1.5.1 | Benign lesions
Published 02/18/2024 GU | Kidney | 1.5.2 | Benign lesions | Angiomyolipoma
Published 02/18/2024 GU | Kidney | 1.5.3 | Benign | Oncocytoma
Published 02/18/2024 GU | Kidney | 1.5.4 | Benign | Haemangioma
Published 02/18/2024 GU | Kidney | 1.5.5 | Benign | Renal papillary adenoma
Published 02/18/2024 GU | Kidney | 1.5.6 | Benign | Leiomyoma
Published 02/18/2024 GU | Kidney | 1.5.7 | Benign | Fibroma (Renomedullary interstitial cell tumour) (Aka medullary fibroma)
Published 02/18/2024 GU | Kidney | 1.6.1 | Molecular pathogenesis
Published 02/18/2024 GU | Kidney | 1.6.2 | Genetic syndromes
Published 02/18/2024 GU | Kidney | 1.7 | RCC | Clinical presentation
Published 02/18/2024 GU | Kidney | 1.8 | DDx
Published 02/18/2024 GU | Kidney | 1.8.1 | RCC | Prognostic factors
Published 02/18/2024 GU | Kidney | 1.9.1 | Staging (AJCC 8th edition 2017)
Published 02/18/2024 GU | Kidney | 1.9.2 | Prognosis by stage
Published 02/18/2024 GU | Kidney | 2 | Workup
Published 02/18/2024 GU | Kidney | 3.1 | Management overview
Published 02/18/2024 GU | Kidney | 3.7.4 | Advanced disease | Clear cell | Summary of systemic agents
Published 02/18/2024 GU | Kidney | 3.2 | Prevention 
Published 02/18/2024 GU | Kidney | 3.3 | Localised disease | <1cm or <3cm high surgical risk | Active surveillance
Published 02/18/2024 GU | Kidney | 3.5.1 | Localised disease | Inoperable | Minimally invasive ablative techniques
Published 02/18/2024 GU | Kidney | 3.4.1 | Localised disease | Operable | Surgery
Published 02/18/2024 GU | Kidney | 3.6.2 | Advanced disease | Surgery | Cytoreductive nephrectomy
Published 02/18/2024 GU | Kidney | 3.6.1 | Advanced disease | Oligometastatic | Metastatectomy
Published 02/18/2024 GU | Kidney | 3.5.2 | Localised disease | Inoperable | SBRT
Published 02/18/2024 GU | Kidney | 3.4.2.1 | Localised disease | Operable | Neoadjuvant RT 
Published 02/18/2024 GU | Kidney | 3.4.2.2 | Localised disease | Operable | Adjuvant RT 
Published 02/18/2024 GU | Kidney | 3.4.2.3 | Localised disease | Operable | Intraoperative RT 
Published 02/18/2024 GU | Kidney | 3.7.1.1 | Advanced disease | Clear cell | Immunotherapy
Published 02/18/2024 GU | Kidney | 3.4.4 | Localised disease | Operable | Adjuvant immunotherapy
Published 02/18/2024 GU | Kidney | 3.7.2.1 | Advanced disease | Clear cell | VEGF TKIs
Published 02/18/2024 GU | Kidney | 3.4.3 | Localised disease | Operable | Adjuvant TKI
Published 02/18/2024 GU | Kidney | 3.7.3 | Advanced disease | Clear cell | mTOR inhibitors (Everolimus)
Published 02/18/2024 GU | Kidney | 5.1 | RT technique | SBRT
Published 02/18/2024 GU | Kidney | 5.2 | RT technique | Adjuvant (but really, don't treat)
Published 02/18/2024 GU | Kidney | 5.3 | RT technique | Neoadjuvant (but really, don't treat)
Published 02/18/2024 GU | Kidney | 1.8.2 | RCC | Prognostic factors | IMDC scoring system (metastatic disease)
Published 02/18/2024 GU | Kidney | 1.5.8 | Grading (clear cell and papillary only - not shown to be prognostic for chromophobe)
Published 02/18/2024 GU | Kidney | 1.1 | Pathologic classification
Published 02/18/2024 GU | Kidney | 3.7.1.2 | Advanced disease | Clear cell | Immunotherapy | Side effects
Published 02/18/2024 GU | Kidney | 3.7.2.2 | Advanced disease | Clear cell | VEGF TKIs | Side effects
Published 02/18/2024 GU | Kidney | 3.7.5 | Advanced disease | Non-clear cell histology
Status Last Update Fields